Recent Updates
Recently added Catalysts

GSK Biologicals HIV Vaccine 732462

Phase 2

AIDS | Monoclonal antibody | Other |GSK plc|Last Updated: May 21, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment191
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01218113Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected PersonsPHASE2 COMPLETED 191Nov 8, 2010Nov 5, 2012May 21, 201842 United States, France +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Geometric Mean Change in Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load (VL) From Baseline
At Week 48, post-Dose 3

Changes from baseline in HIV-1 viral load (ratio of each value over baseline value) were obtained using crude values and expressed in RNA copies/milliliter \[copies/mL\]. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic.

Geometric Mean Change in HIV-1 VL From Baseline
At Week 48, post-Dose 3

Changes from baseline in HIV-1 viral load (difference of each value minus baseline value) were obtained using log10-transformed values and expressed in log10-RNA copies/mL. Baseline of HIV-1 viral load was defined as geometric mean of values measured in blood samples taken at Screening and at Week 0. The HIV type 1, represents the more aggressive virus form, largely responsible for the AIDS pandemic.

Number of Subjects With Solicited Local Symptoms
During the 7-day (Days 0-6) period following Dose 1

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of symptom regardless of intensity. Grade 3 Pain = pain that prevented normal every day activities. Grade 3 Redness/Swelling = redness or swelling associated with ulceration or secondary infection/phlebitis/sterile abscess/drainage. Medically attended (MA) Pain = pain causing inability to perform basic self-care function or Hospitalization indicated for management of pain. Medically attended Redness/Swelling = redness or swelling associated with necrosis.

Number of Subjects With Solicited General Symptoms
During the 7-day (Days 0-6) period following Dose 1

Assessed solicited general symptoms(smt.)were abdominalpain,anorexia,diarrhoea,fatigue,headache,myalgia,nausea,sweating,temperature(Temp.)orally=temp.37.7degreesCelsius(°C)\&vomiting.Any=occurrene of smt.regardless of intensity.Grade3(G3)Abdominal pain/fatigue/myalgia/sweating/headache=symp.causing inability to perform usual social\&functional activities.Medicallyattended(MA)Abdominalpain/fatigue/myalgia/sweating/headache=smt.causing inability to perform basic self-care activities.G3Anorexia=loss of appetite associated with significant weight loss.MAanorexia=aggressive intervention indicated.G3diarrhoea=blood/increased≥7stools per24hours(h)/4fluid replacement.G3nausea=persistent nausea resulting in minimal oral intake for more than48h/with aggressive rehydration indicated.G3vomiting=persistent vomiting resulting in orthostatic hypotension/aggressive.MAdiarrhoea/nausea/vomiting=smt.with life threatening consequences.Related=smt.assessed by the investigator as being related to vaccination

Number of Subjects With Unsolicited Adverse Events (AEs)
During the 28-Day (Days 0-27) period following Dose 1 and Dose 2

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 (G3) AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were tabulated following Dose 1 and Dose 2 vaccinations.

Number of Subjects With Unsolicited AEs
During the 28-Day (Days 0-27) post-vaccination period

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 (G3) AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were tabulated following Dose 3 and across doses.

Number of Subjects With Serious Adverse Events (SAEs)
During the entire study period (up to Week 48)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Number of Subjects With Potentially Immune-Mediated Diseases (pIMDs)
During the entire study period (up to Week 48)

Potentially Immune-Mediated Diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.

Number of Subjects With Abnormal Haematological and Biochemical Values
At Screening

Among the biochemical and haematological parameters with abnormal values were alanine aminotransferase \[ALT\], albumin \[ALB\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin (total) \[BIL\], creatinine \[CRE\], eosinophils \[EOS\], eosinophils/100 leukocytes \[EOS/100LEU\], bicarbonate \[BIC\], haemoglobin \[HGB\], potassium \[PTS\], lymphocytes \[LYM\], lymphocytes/100 leukocytes \[LYM/100LEU\], sodium \[SDI\], neutrophils \[NEU\], neutrophils/100 leukocytes \[NEU/100LEU\], platelet count \[PLC\], prothrombin time-international normalized ratio \[PTT\] and white blood cell count \[WBC\]. Assessed grades (G) for laboratory parameters were 0, 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening), according to DAIDS (division of AIDS table for grading the severity of adult and pediatric adverse events -Version 1.0).

Secondary Endpoints
Geometric Mean Change in HIV-1 Viral Load (LV) From Baseline
At Weeks 1, 4, 6, 16, 28, 30 and 38
Geometric Mean Change in HIV-1 VL From Baseline
At Weeks 1, 4, 6, 16, 28, 30 and 38
Levels of HIV-1 Viral Load (VL)
At Screening, Pre-vaccination and at Weeks 1, 4, 6, 16, 28, 30, 38 and 48
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
3D_HIV GroupEXPERIMENTALHIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
2D_HIV GroupEXPERIMENTALHIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm.
Control GroupPLACEBO_COMPARATORHIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
Interventions
NameTypeDescription
GSK Biologicals HIV Vaccine 732462BIOLOGICAL2 or 3 doses according to protocol schedule
PlaceboDRUG1 or 3 doses according to protocol schedule
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersNo
Study Sites42

Inclusion Criteria: All subjects must satisfy ALL the following criteria at study entry: * Subjects who the investigator believes can and will comply with the requirements of the protocol. * Written informed consent obtained from the subject prior to any study procedure. * A male or female between...

Countries:United StatesFranceGermanySpain
Unlock Eligibility Criteria